[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"$fDIImpTqUS5GsnXglf1p0kSxf7lXj7yGtKE9U3d0nGPc":3},{"sponsor":4,"sponsorVariants":5,"totalTrials":6,"truncated":7,"activeTrials":8,"phase3Count":9,"totalEnrollment":10,"activePrograms":11,"nonDrugCount":12,"topConditions":13,"upcomingReadouts":32,"phaseBuckets":38,"rows":45},"University of Lausanne Hospitals",[4],118,false,6,2,24142,1,105,[14,17,19,22,24,26,28,30],{"name":15,"count":16},"Stress",4,{"name":18,"count":16},"Obesity",{"name":20,"count":21},"Coronary Artery Disease",3,{"name":23,"count":21},"Knee Osteoarthritis",{"name":25,"count":21},"Physical Activity",{"name":27,"count":21},"Prostate Cancer",{"name":29,"count":21},"Nasal Obstruction",{"name":31,"count":9},"Cardiovascular Diseases",[33],{"nctId":34,"briefTitle":35,"date":36,"intervention":37},"NCT01608516","Multimodal Imaging Assessment of the Inflammatory Atheromatous Plaque","2024-12","68Ga-NODAGA-RGD PET\u002FCT",[39,40,41,42,43,44],"EARLY_PHASE1","PHASE1","PHASE2","PHASE3","PHASE4","NA",[46,83,110,138,156,174,200,218,243,268,295,313,337,362,389,407,425,450],{"intervention":37,"totalTrials":9,"cells":47},{"EARLY_PHASE1":48,"PHASE1":51,"PHASE2":65,"PHASE3":77,"PHASE4":79,"NA":81},{"trials":49,"activeCount":50},[],0,{"trials":52,"activeCount":50},[53],{"nctId":54,"briefTitle":55,"status":56,"phases":57,"primaryCompletion":58,"completion":59,"start":60,"enrollment":61,"conditions":62,"interventions":64},"NCT02666547","68Ga-NODAGA-RGD PET\u002F CT for Tumoral Neoangiogenesis","TERMINATED",[40],"2023-08","2023-09","2014-03",42,[63],"Pathological Angiogenesis",[37],{"trials":66,"activeCount":11,"soonestReadout":36},[67],{"nctId":34,"briefTitle":35,"status":68,"phases":69,"primaryCompletion":36,"completion":36,"start":70,"enrollment":71,"conditions":72,"interventions":76},"RECRUITING",[40,41],"2012-04",20,[73,74,75],"Inflammation","Atheromatous Plaques","Carotid Artery Diseases",[37],{"trials":78,"activeCount":50},[],{"trials":80,"activeCount":50},[],{"trials":82,"activeCount":50},[],{"intervention":84,"totalTrials":11,"cells":85},"Metronidazole",{"EARLY_PHASE1":86,"PHASE1":88,"PHASE2":90,"PHASE3":92,"PHASE4":94,"NA":108},{"trials":87,"activeCount":50},[],{"trials":89,"activeCount":50},[],{"trials":91,"activeCount":50},[],{"trials":93,"activeCount":50},[],{"trials":95,"activeCount":50},[96],{"nctId":97,"briefTitle":98,"status":99,"phases":100,"primaryCompletion":101,"completion":102,"start":103,"enrollment":104,"conditions":105,"interventions":107},"NCT01521403","Is it Effective to Treat Patients With Blastocystis Hominis Infection?","UNKNOWN",[43],"2018-12-31","2022-12-30","2012-11",200,[106],"Blastocystis Hominis Infections",[84],{"trials":109,"activeCount":50},[],{"intervention":111,"totalTrials":11,"cells":112},"Intanza",{"EARLY_PHASE1":113,"PHASE1":115,"PHASE2":117,"PHASE3":132,"PHASE4":134,"NA":136},{"trials":114,"activeCount":50},[],{"trials":116,"activeCount":50},[],{"trials":118,"activeCount":50},[119],{"nctId":120,"briefTitle":121,"status":122,"phases":123,"primaryCompletion":124,"completion":124,"start":125,"enrollment":126,"conditions":127,"interventions":129},"NCT02960815","Imiquimod and Influenza Vaccine for Immunocompromised Patients","COMPLETED",[41],"2017-06","2016-11",70,[128],"Influenza Vaccine",[111,130,131],"Mutagrip","Aldara",{"trials":133,"activeCount":50},[],{"trials":135,"activeCount":50},[],{"trials":137,"activeCount":50},[],{"intervention":130,"totalTrials":11,"cells":139},{"EARLY_PHASE1":140,"PHASE1":142,"PHASE2":144,"PHASE3":150,"PHASE4":152,"NA":154},{"trials":141,"activeCount":50},[],{"trials":143,"activeCount":50},[],{"trials":145,"activeCount":50},[146],{"nctId":120,"briefTitle":121,"status":122,"phases":147,"primaryCompletion":124,"completion":124,"start":125,"enrollment":126,"conditions":148,"interventions":149},[41],[128],[111,130,131],{"trials":151,"activeCount":50},[],{"trials":153,"activeCount":50},[],{"trials":155,"activeCount":50},[],{"intervention":131,"totalTrials":11,"cells":157},{"EARLY_PHASE1":158,"PHASE1":160,"PHASE2":162,"PHASE3":168,"PHASE4":170,"NA":172},{"trials":159,"activeCount":50},[],{"trials":161,"activeCount":50},[],{"trials":163,"activeCount":50},[164],{"nctId":120,"briefTitle":121,"status":122,"phases":165,"primaryCompletion":124,"completion":124,"start":125,"enrollment":126,"conditions":166,"interventions":167},[41],[128],[111,130,131],{"trials":169,"activeCount":50},[],{"trials":171,"activeCount":50},[],{"trials":173,"activeCount":50},[],{"intervention":175,"totalTrials":11,"cells":176},"Single dose MUTAGRIP® influenza vaccine",{"EARLY_PHASE1":177,"PHASE1":179,"PHASE2":181,"PHASE3":194,"PHASE4":196,"NA":198},{"trials":178,"activeCount":50},[],{"trials":180,"activeCount":50},[],{"trials":182,"activeCount":50},[183],{"nctId":184,"briefTitle":185,"status":122,"phases":186,"primaryCompletion":187,"completion":187,"start":188,"enrollment":189,"conditions":190,"interventions":192},"NCT02746783","Immunogenicity and Safety of the Seasonal Flu Vaccine in Elderly and in SOT Recipients",[40,41],"2015-07","2013-10",163,[191],"Healthy Volunteers",[175,193],"Double dose of MUTAGRIP® influenza vaccine",{"trials":195,"activeCount":50},[],{"trials":197,"activeCount":50},[],{"trials":199,"activeCount":50},[],{"intervention":193,"totalTrials":11,"cells":201},{"EARLY_PHASE1":202,"PHASE1":204,"PHASE2":206,"PHASE3":212,"PHASE4":214,"NA":216},{"trials":203,"activeCount":50},[],{"trials":205,"activeCount":50},[],{"trials":207,"activeCount":50},[208],{"nctId":184,"briefTitle":185,"status":122,"phases":209,"primaryCompletion":187,"completion":187,"start":188,"enrollment":189,"conditions":210,"interventions":211},[40,41],[191],[175,193],{"trials":213,"activeCount":50},[],{"trials":215,"activeCount":50},[],{"trials":217,"activeCount":50},[],{"intervention":219,"totalTrials":11,"cells":220},"Melan-A analog peptide",{"EARLY_PHASE1":221,"PHASE1":223,"PHASE2":235,"PHASE3":237,"PHASE4":239,"NA":241},{"trials":222,"activeCount":50},[],{"trials":224,"activeCount":50},[225],{"nctId":226,"briefTitle":227,"status":228,"phases":229,"completion":230,"start":231,"enrollment":8,"conditions":232,"interventions":234},"NCT00160992","Adoptive Cell Transfer Combined With Peptide Vaccination in Transiently Immunosuppressed Melanoma Patients","SUSPENDED",[40],"2005-08","2004-07",[233],"Melanoma",[219],{"trials":236,"activeCount":50},[],{"trials":238,"activeCount":50},[],{"trials":240,"activeCount":50},[],{"trials":242,"activeCount":50},[],{"intervention":244,"totalTrials":11,"cells":245},"Vaccin rabique Pasteur®",{"EARLY_PHASE1":246,"PHASE1":248,"PHASE2":260,"PHASE3":262,"PHASE4":264,"NA":266},{"trials":247,"activeCount":50},[],{"trials":249,"activeCount":50},[250],{"nctId":251,"briefTitle":252,"status":122,"phases":253,"primaryCompletion":254,"completion":254,"start":255,"enrollment":256,"conditions":257,"interventions":259},"NCT02538185","Intradermal Rabies Immunization Using NanoJect: A Comparative Study",[40],"2014-09","2013-08",66,[258],"Intradermal (ID) Vaccination Device",[244],{"trials":261,"activeCount":50},[],{"trials":263,"activeCount":50},[],{"trials":265,"activeCount":50},[],{"trials":267,"activeCount":50},[],{"intervention":269,"totalTrials":11,"cells":270},"[18F]-AzaFol",{"EARLY_PHASE1":271,"PHASE1":273,"PHASE2":287,"PHASE3":289,"PHASE4":291,"NA":293},{"trials":272,"activeCount":50},[],{"trials":274,"activeCount":50},[275],{"nctId":276,"briefTitle":277,"status":122,"phases":278,"primaryCompletion":279,"completion":279,"start":280,"enrollment":281,"conditions":282,"interventions":285},"NCT03242993","[18F]-AZAFOL AS POSITRON EMISSION TOMOGRAPHY (PET) TRACER in FR Positive Cancer Imaging",[40],"2019-06-01","2017-04-01",15,[283,284],"Metastatic Cancer Lung","Metastatic Ovarian Cancer",[269,286],"folarell",{"trials":288,"activeCount":50},[],{"trials":290,"activeCount":50},[],{"trials":292,"activeCount":50},[],{"trials":294,"activeCount":50},[],{"intervention":286,"totalTrials":11,"cells":296},{"EARLY_PHASE1":297,"PHASE1":299,"PHASE2":305,"PHASE3":307,"PHASE4":309,"NA":311},{"trials":298,"activeCount":50},[],{"trials":300,"activeCount":50},[301],{"nctId":276,"briefTitle":277,"status":122,"phases":302,"primaryCompletion":279,"completion":279,"start":280,"enrollment":281,"conditions":303,"interventions":304},[40],[283,284],[269,286],{"trials":306,"activeCount":50},[],{"trials":308,"activeCount":50},[],{"trials":310,"activeCount":50},[],{"trials":312,"activeCount":50},[],{"intervention":314,"totalTrials":11,"cells":315},"123I radiolabeled 3BNC117",{"EARLY_PHASE1":316,"PHASE1":327,"PHASE2":329,"PHASE3":331,"PHASE4":333,"NA":335},{"trials":317,"activeCount":50},[318],{"nctId":319,"briefTitle":320,"status":122,"phases":321,"primaryCompletion":322,"completion":322,"start":323,"enrollment":8,"conditions":324,"interventions":326},"NCT03468582","123I Radiolabeled 3BNC117",[39],"2020-01-28","2018-02-08",[325],"Human Immunodeficiency Virus",[314],{"trials":328,"activeCount":50},[],{"trials":330,"activeCount":50},[],{"trials":332,"activeCount":50},[],{"trials":334,"activeCount":50},[],{"trials":336,"activeCount":50},[],{"intervention":338,"totalTrials":11,"cells":339},"Outpatient parenteral antimicrobial therapy",{"EARLY_PHASE1":340,"PHASE1":342,"PHASE2":344,"PHASE3":346,"PHASE4":348,"NA":350},{"trials":341,"activeCount":50},[],{"trials":343,"activeCount":50},[],{"trials":345,"activeCount":50},[],{"trials":347,"activeCount":50},[],{"trials":349,"activeCount":50},[],{"trials":351,"activeCount":50},[352],{"nctId":353,"briefTitle":354,"status":99,"phases":355,"primaryCompletion":356,"completion":356,"start":357,"enrollment":358,"conditions":359,"interventions":361},"NCT03221140","Outpatient Parenteral Antimicrobial Therapy (OPAT)",[],"2025-12-31","2014-01-01",2000,[360],"Infections",[338],{"intervention":363,"totalTrials":11,"cells":364},"Lidocaine,",{"EARLY_PHASE1":365,"PHASE1":367,"PHASE2":369,"PHASE3":371,"PHASE4":373,"NA":375},{"trials":366,"activeCount":50},[],{"trials":368,"activeCount":50},[],{"trials":370,"activeCount":50},[],{"trials":372,"activeCount":50},[],{"trials":374,"activeCount":50},[],{"trials":376,"activeCount":50},[377],{"nctId":378,"briefTitle":379,"status":122,"phases":380,"primaryCompletion":381,"completion":381,"start":382,"enrollment":383,"conditions":384,"interventions":386},"NCT01439399","Analgesic Efficacy of Intravenous Lidocaine and\u002For Ketamine",[44],"2007-07","2005-12",52,[385],"Postoperative Pain",[363,387,388],"Ketamine","association ketamine-lidocaine",{"intervention":387,"totalTrials":11,"cells":390},{"EARLY_PHASE1":391,"PHASE1":393,"PHASE2":395,"PHASE3":397,"PHASE4":399,"NA":401},{"trials":392,"activeCount":50},[],{"trials":394,"activeCount":50},[],{"trials":396,"activeCount":50},[],{"trials":398,"activeCount":50},[],{"trials":400,"activeCount":50},[],{"trials":402,"activeCount":50},[403],{"nctId":378,"briefTitle":379,"status":122,"phases":404,"primaryCompletion":381,"completion":381,"start":382,"enrollment":383,"conditions":405,"interventions":406},[44],[385],[363,387,388],{"intervention":388,"totalTrials":11,"cells":408},{"EARLY_PHASE1":409,"PHASE1":411,"PHASE2":413,"PHASE3":415,"PHASE4":417,"NA":419},{"trials":410,"activeCount":50},[],{"trials":412,"activeCount":50},[],{"trials":414,"activeCount":50},[],{"trials":416,"activeCount":50},[],{"trials":418,"activeCount":50},[],{"trials":420,"activeCount":50},[421],{"nctId":378,"briefTitle":379,"status":122,"phases":422,"primaryCompletion":381,"completion":381,"start":382,"enrollment":383,"conditions":423,"interventions":424},[44],[385],[363,387,388],{"intervention":426,"totalTrials":11,"cells":427},"tobramycin",{"EARLY_PHASE1":428,"PHASE1":430,"PHASE2":432,"PHASE3":434,"PHASE4":436,"NA":438},{"trials":429,"activeCount":50},[],{"trials":431,"activeCount":50},[],{"trials":433,"activeCount":50},[],{"trials":435,"activeCount":50},[],{"trials":437,"activeCount":50},[],{"trials":439,"activeCount":50},[440],{"nctId":441,"briefTitle":442,"status":122,"phases":443,"primaryCompletion":444,"start":445,"enrollment":446,"conditions":447,"interventions":449},"NCT01938417","Tobramycin Exposure From Active Calcium Sulfate Bone Graft Substitute",[],"2008-03","2006-10",12,[448],"Orthopedic Operations",[426],{"intervention":451,"totalTrials":11,"cells":452},"Blood test",{"EARLY_PHASE1":453,"PHASE1":455,"PHASE2":457,"PHASE3":459,"PHASE4":461,"NA":463},{"trials":454,"activeCount":50},[],{"trials":456,"activeCount":50},[],{"trials":458,"activeCount":50},[],{"trials":460,"activeCount":50},[],{"trials":462,"activeCount":50},[],{"trials":464,"activeCount":50},[465],{"nctId":466,"briefTitle":467,"status":122,"phases":468,"primaryCompletion":469,"completion":470,"start":471,"enrollment":472,"conditions":473,"interventions":475},"NCT04638335","What is the Anti-HAV Seroprevalence of Travelers >60 Years or Having Lived in a Tropical Country for >5 Years",[],"2021-12-31","2022-03-31","2019-10-06",50,[474],"Hepatitis A",[451]]